Synopsis
Explain how cytotoxic regimens are selected and delivered, verify treatment safety before every cycle, prevent dosing and route errors, and respond rapidly to neutropenic sepsis and organ-specific toxicity.
- Cytotoxic medicines damage dividing cells through DNA injury, antimetabolite action, mitotic disruption or topoisomerase effects; combinations attack different vulnerabilities but compound toxicity.
- Regimen choice depends on histology, stage, intent, biomarkers, prior therapy, organ function and patient goals; the protocol specifies medicines, sequence, cycle and modifications.
- Before every cycle verify identity, consent, intent, performance, blood count, renal and hepatic function, toxicity, infection and dose changes through an independent SACT process.
- Dosing may use body surface area, weight, renal function or exposure-based calculation; never reconstruct a regimen from memory or copy a previous cycle blindly.
- Myelosuppression, mucositis, nausea, diarrhoea, alopecia, infertility and fatigue are common, while individual agents add cardiac, renal, pulmonary, neurological or bladder toxicity.
- Supportive antiemetics, growth-factor prophylaxis, hydration and infection prevention are regimen-specific and should be prescribed with the anticancer medicines.
- Suspected neutropenic sepsis is an acute medical emergency: assess and culture without delaying the first empirical antibiotic, aiming to administer it within 1 hour of acute presentation; a normal temperature or pending blood count does not make deterioration safe.
- Provide a 24-hour treatment line, written warning symptoms, reproductive advice and a medication-interaction plan before the first dose.
Key red flags
Fever, shivering, hypotension, confusion or unexplained deterioration after treatment needs immediate emergency antibiotics and sepsis care.
Pain, swelling, erythema, resistance or absent blood return during vesicant infusion requires immediate stop and agent-specific management.
Investigation priorities
Confirm marrow recovery and detect anaemia or thrombocytopenia.
Management branches
A patient attends for protocol-based cytotoxic treatment.
- Confirm identity, diagnosis, intent, consent, regimen, cycle, body size or renal calculation, allergies and previous dose modifications.
- Review performance, infection, toxicity, full blood count, renal, hepatic and agent-specific results against the current protocol.
- Authorise, delay, reduce or stop with documented rationale and independent pharmacy and administration checks; prescribe supportive care concurrently.
Key medicines
Capecitabine (oral cytotoxic example)A licensed monotherapy schedule is 1,250 mg/m² orally twice daily on days 1–14 of a 21-day cycle, taken within 30 minutes after food; combination protocols commonly use different starting doses. Calculate each dose and apply protocol, renal and toxicity modifications rather than copying this example.Check dihydropyrimidine dehydrogenase status before treatment. Diarrhoea, mucositis, hand-foot syndrome, marrow suppression and cardiotoxicity require prompt holds; severe renal impairment is contraindicated and major interactions include coumarin anticoagulants.
Piperacillin/tazobactam for suspected neutropenic sepsisGive the first adult dose 4.5 g intravenously immediately; the licensed febrile-neutropenia schedule is 4.5 g every 6 hours, then modify to local microbiology, allergy, prior resistance, cultures and renal function. Do not add an aminoglycoside or glycopeptide routinely without a patient-specific or local indication.Take cultures without delaying treatment, verify severe beta-lactam allergy, adjust for renal impairment, review sodium load and monitor blood count, kidney, liver and microbiology. Escalate shock and source control in parallel.